LAU-7b is a novel and proprietary oral formulation of fenretinide, an atypical retinoid with well-established safety and efficacy in respiratory diseases and macular degeneration.

Existing preclinical and clinical data suggest that low-dose fenretinide has the potential to modulate multiple molecular pathways involved in inflammation, fibrosis and degeneration, via dual retinoid and nonretinoid mechanism.